Hormone exposure and venous thromboembolism in commercially insured women aged 50 to 64 years

BACKGROUND: Menopausal hormone therapy (MHT) can elevate venous thromboembolism (VTE) risk, but less is known about formulations and routes of exposures. OBJECTIVE: To estimate hormone-associated VTE risk by route and formulation in exposed and unexposed women aged 50 to 64 years in the US. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Weller, Susan C., Davis, John W., Porterfield, Laura, Chen, Lu, Wilkinson, Gregg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182313/
https://www.ncbi.nlm.nih.gov/pubmed/37193125
http://dx.doi.org/10.1016/j.rpth.2023.100135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182313/
https://www.ncbi.nlm.nih.gov/pubmed/37193125
http://dx.doi.org/10.1016/j.rpth.2023.100135

Ejemplares similares